Skip to Main content Skip to Navigation
Journal articles

Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies

Abstract : Background : Targeted therapies, in particular antiangiogenic therapies (AATs), have become the standard of treatment for metastatic renal cell carcinoma (mRCC). Although common adverse effects like fatigue have been well-established, sexual disorders induced by these treatments, although often reported, have been poorly evaluated. The aim of this study was to evaluate the impact of AATs on the sexual life of patients with mRCC and the relationships with quality of life (QoL), fatigue, and biologic parameters. Patients and Methods : This longitudinal study included patients with mRCC on first- or second-line AATs. Sexuality was evaluated by the French version of Changes in Sexual Functioning Questionnaire short-Form (CSFQ); QoL and fatigue were measured by the Functional Assessment of Cancer Therapy General (FACT-G) and the Multidimensional Fatigue Inventory (MFI-20), respectively. Biologic parameters were also assessed. Results : Among 75 patients included in the study, 39 agreed to respond to the sexual functioning questionnaire (CSFQ). At baseline, all patients had at least 1 sexual dysfunction. No relationship with QoL, fatigue, and biologic parameters was shown. After 3 months of treatment, a decrease in at least 1 sexual dimension was observed in 69% of patients. The most affected sexual dimensions were pleasure (34%) and desire/interest (38%). No significant relationship between sexual dysfunctions and biologic parameters was found. The percentage of non-participants (50%) and the absence of a control arm are the main limitations. Discussion : Patients with mRCC exhibit sexual dysfunction that could be increased by AATs independently of the impact on fatigue and QoL. Further studies aiming to define the role of biologic parameters like inflammatory markers and thyroid parameters are warranted. Conclusion : Sexual disorders induced or degraded by AAT are an independent side effect that should be taken into account in oncology supportive care departments.
Document type :
Journal articles
Complete list of metadata
Contributor : Hélène Castel <>
Submitted on : Friday, September 6, 2019 - 12:23:30 AM
Last modification on : Friday, February 26, 2021 - 3:18:50 AM



Angeline Denouel, Natacha Heutte, Bernard Escudier, Jean-Emmanuel Kurtz, Mélanie dos Santos, et al.. Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies. Clinical Genitourinary Cancer, Elsevier, 2018, 16 (5), pp.369-375.e1. ⟨10.1016/j.clgc.2018.05.013⟩. ⟨hal-02280077⟩



Record views